Sangal Papers Ltd Upgraded to Sell on Technical Improvement and Valuation Appeal

Quality Assessment: Weak Fundamentals Persist

Sangal Papers continues to exhibit weak long-term fundamental strength, which remains a significant concern for investors. The company’s average Return on Capital Employed (ROCE) stands at a modest 6.69%, indicating limited efficiency in generating profits from its capital base. Over the past five years, net sales have grown at an annualised rate of 13.86%, while operating profit has increased by 18.76%. Although these growth rates are positive, they are not sufficiently robust to offset other weaknesses.

Moreover, the company’s ability to service debt is under pressure, with a high Debt to EBITDA ratio of 4.33 times. This elevated leverage level raises concerns about financial risk, especially in volatile market conditions. Adding to the risk profile, 38.76% of promoter shares are pledged, which could exert additional downward pressure on the stock price during market downturns.

Quarterly financial performance remains flat, with the latest Q3 FY25-26 results showing no significant improvement. Profitability has also deteriorated, with profits falling by 42.3% over the past year. These factors collectively contribute to the company’s low Mojo Grade of Sell, despite the recent upgrade from Strong Sell.

Valuation: Attractive but Reflective of Risks

From a valuation perspective, Sangal Papers presents a very attractive profile. The company’s ROCE of 5.3% combined with an Enterprise Value to Capital Employed ratio of 0.7 indicates that the stock is trading at a discount relative to its peers’ historical valuations. This discount suggests potential value for investors willing to accept the associated risks.

However, the stock’s recent price performance has been disappointing. It closed at ₹185.00 on 10 March 2026, up 2.49% from the previous close of ₹180.50, but remains well below its 52-week high of ₹285.00. The 52-week low stands at ₹151.10, highlighting significant price volatility. Despite the attractive valuation, the market’s cautious stance is evident in the stock’s underperformance relative to benchmarks.

Over the last year, Sangal Papers has generated a negative return of -12.32%, in stark contrast to the BSE500’s positive return of 7.32%. This underperformance reflects investor concerns about the company’s fundamentals and market positioning.

Financial Trend: Flat Performance Amidst Market Challenges

The financial trend for Sangal Papers remains largely flat, with the company reporting no significant growth in the most recent quarter. The flat Q3 FY25-26 results underscore the challenges faced in improving operational efficiency and profitability. While net sales and operating profit have shown moderate growth over five years, the recent decline in profits by 42.3% over the past year signals deteriorating earnings quality.

Debt servicing remains a critical issue, with the high Debt to EBITDA ratio of 4.33 times limiting financial flexibility. This elevated leverage, combined with the substantial promoter share pledge, increases the risk of financial distress in adverse market conditions. Investors should weigh these factors carefully when considering the stock’s prospects.

Despite these concerns, the company’s long-term returns have been relatively strong. Over five and ten years, Sangal Papers has delivered returns of 167.73% and 253.05% respectively, outperforming the Sensex’s 52.01% and 212.84% returns over the same periods. This long-term outperformance suggests that the company has underlying strengths that could be leveraged if operational and financial issues are addressed.

Technicals: Shift from Bearish to Mildly Bearish Supports Upgrade

The primary driver behind the recent upgrade in Sangal Papers’ investment rating is the improvement in technical indicators. The technical grade shifted from bearish to mildly bearish, signalling a less negative market sentiment. Key technical metrics present a mixed but cautiously optimistic picture:

• MACD: Weekly readings are mildly bullish, although monthly indicators remain bearish.
• RSI: Weekly RSI is bullish, suggesting short-term momentum, while monthly RSI shows no clear signal.
• Bollinger Bands: Weekly bands indicate mild bearishness, with monthly bands confirming bearish trends.
• Moving Averages: Daily averages remain bearish, reflecting recent price weakness.
• KST (Know Sure Thing): Weekly readings are mildly bullish, but monthly remain bearish.
• Dow Theory: Weekly trend shows no clear direction, while monthly trend is mildly bullish.

These mixed signals suggest that while the stock is not yet in a strong uptrend, the technical outlook has improved sufficiently to warrant a rating upgrade. The stock price’s recent rise to ₹185.00, with a day high of ₹189.50, supports this view. However, the overall technical environment remains cautious, reflecting the underlying fundamental challenges.

Market Performance and Outlook

Despite the technical upgrade, Sangal Papers has underperformed the broader market in recent periods. The stock’s one-week return was -1.07%, compared to the Sensex’s -3.33%, and its one-month return was -5.64%, slightly better than the Sensex’s -7.73%. Year-to-date, the stock has declined by 0.59%, outperforming the Sensex’s -8.98% decline. However, over the last year, the stock’s -12.32% return contrasts sharply with the Sensex’s positive 4.35% gain.

Longer-term returns remain favourable, with three-year returns of 19.20% and five-year returns of 167.73%, both trailing the Sensex’s 29.70% and 52.01% respectively but still indicating solid growth over time. The ten-year return of 253.05% notably outpaces the Sensex’s 212.84%, reflecting the company’s historical ability to generate shareholder value.

Given the mixed signals from fundamentals and technicals, investors should approach Sangal Papers with caution. The recent upgrade to Sell from Strong Sell reflects a modest improvement in technical outlook but does not yet signal a full recovery or strong buy opportunity.

Conclusion: A Cautious Upgrade Amidst Lingering Risks

Sangal Papers Ltd’s investment rating upgrade to Sell from Strong Sell is primarily driven by improved technical indicators, signalling a less bearish market sentiment. However, fundamental challenges remain significant, including weak profitability, high leverage, flat recent financial performance, and substantial promoter share pledging. Valuation metrics suggest the stock is attractively priced relative to peers, but this discount reflects the risks investors face.

While the company’s long-term returns have been commendable, recent underperformance and deteriorating profits caution against aggressive positioning. Investors should monitor upcoming quarterly results and technical trends closely before considering exposure. The current rating reflects a cautious stance, recognising technical improvements but acknowledging persistent fundamental headwinds.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →